Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
14 studies found for:    vaccine[TREATMENT] AND lymphoma NOT myeloma [ALL-FIELDS] | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Idiotypic Vaccination for Follicular Lymphoma Patients
Conditions: Follicular Lymphoma;   First Relapse/Progression
Intervention: Biological: Follicular lymphoma, patient-specific, soluble protein idiotype vaccine
2 Not yet recruiting Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma
Condition: Follicular Lymphoma
Intervention: Biological: Oncoquest-L vaccine
3 Not yet recruiting Personalized Synthetic Long Peptide Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Biological: Personalized synthetic long peptide vaccine;   Drug: Poly ICLC;   Biological: Nivolumab;   Procedure: Peripheral blood draws;   Procedure: Leukapheresis;   Biological: Rituximab;   Procedure: Biopsy
4 Recruiting Low Grade Lymphoma
Condition: Indolent Lymphoproliferative Disorders
Intervention: Biological: Vaccin GenHevac B Pasteur
5 Recruiting Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Biological: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Pneumococcal 13-valent Conjugate Vaccine;   Other: Quality-of-Life Assessment;   Biological: Trivalent Influenza Vaccine
6 Recruiting Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
Conditions: Monoclonal B-Cell Lymphocytosis;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Biological: Pneumococcal 13-valent Conjugate Vaccine
7 Recruiting A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL
Condition: Diffuse Large B-Cell Lymphoma
Interventions: Biological: DPX-Survivac;   Drug: Cyclophosphamide
8 Recruiting Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Aggressive Non-Hodgkin Lymphoma;   Indolent Non-Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Small Lymphocytic Lymphoma
Interventions: Procedure: Cryosurgery;   Biological: Dendritic Cell Therapy;   Biological: Pembrolizumab;   Biological: Pneumococcal 13-valent Conjugate Vaccine;   Other: Quality-of-Life Assessment
9 Recruiting In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
Condition: Low-Grade B-cell Lymphoma
Interventions: Drug: rhuFlt3L/CDX-301;   Drug: Poly-ICLC
10 Recruiting Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Lymphocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cytomegaloviral Infection;   Hodgkin Lymphoma;   Lymphadenopathy;   Lymphoblastic Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine;   Other: Placebo
11 Recruiting Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Hodgkin Lymphoma;   Adult Non-Hodgkin Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cytomegaloviral Infection;   Hematopoietic and Lymphoid Cell Neoplasm;   HLA-A*0201 Positive Cells Present;   Myelodysplastic Syndrome;   Adult Lymphoblastic Lymphoma;   Chronic Lymphocytic Leukemia;   Myelofibrosis;   Myeloproliferative Neoplasm
Interventions: Biological: CMVpp65-A*0201 peptide vaccine;   Other: Placebo;   Other: Laboratory Biomarker Analysis
12 Recruiting Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Radiation: Radiotherapy;   Biological: Rituximab;   Biological: Autologous dendritic cells;   Biological: GM-CSF;   Biological: Pembrolizumab
13 Recruiting A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
Conditions: Head and Neck Squamous Cell Carcinoma;   Breast Cancer;   Sarcoma;   Merkel Cell Carcinoma;   Cutaneous T-Cell Lymphoma;   Melanoma;   Renal Cancer;   Bladder Cancer;   Prostate Cancer
Interventions: Drug: Durvalumab;   Drug: Tremelimumab;   Drug: Poly ICLC
14 Recruiting Vaccinating Children After Chemotherapy
Condition: Acute Lymphoblastic Leukemia
Interventions: Biological: Prevnar®13;   Biological: Pneumovax® 23;   Biological: Pediacel®

Study has passed its completion date and status has not been verified in more than two years.